Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Corcept Therapeutics (NQ: CORT ) 47.62 -1.35 (-2.76%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,462,090 Open 48.61 Bid (Size) 46.08 (2) Ask (Size) 49.08 (2) Prev. Close 48.97 Today's Range 46.38 - 48.97 52wk Range 20.84 - 50.07 Shares Outstanding 115,926,629 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Wednesday's After-Market Session October 30, 2024 Via Benzinga Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update October 30, 2024 From Corcept Therapeutics Incorporated Via Business Wire Performance YTD +97.10% +97.10% 1 Month +4.82% +4.82% 3 Month +37.99% +37.99% 6 Month +98.66% +98.66% 1 Year +83.79% +83.79% More News Read More Earnings Preview: Corcept Therapeutics October 29, 2024 Via Benzinga Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call October 23, 2024 From Corcept Therapeutics Incorporated Via Business Wire Key Takeaways From Corcept Therapeutics Analyst Ratings October 18, 2024 Via Benzinga Is NASDAQ:CORT suited for high growth investing? October 17, 2024 Via Chartmill NASDAQ:CORT: a strong growth stock preparing for the next leg up?. October 14, 2024 Via Chartmill Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. October 08, 2024 Via Chartmill Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast September 30, 2024 Via Benzinga Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics September 18, 2024 Via Benzinga NASDAQ:CORT is not too expensive for the growth it is showing. September 17, 2024 Via Chartmill NASDAQ:CORT: a strong growth stock preparing for the next leg up?. September 09, 2024 Via Chartmill For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. August 27, 2024 Via Chartmill NASDAQ:CORT: a strong growth stock preparing for the next leg up?. August 16, 2024 Via Chartmill NASDAQ:CORT is not too expensive for the growth it is showing. August 05, 2024 Via Chartmill Unveiling 8 Analyst Insights On Corcept Therapeutics July 30, 2024 Via Benzinga CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024 July 29, 2024 Via InvestorPlace Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update July 29, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call July 22, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation. July 15, 2024 Via Chartmill Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. July 15, 2024 Via Chartmill 7 Biotech Stocks to Boost Your Portfolio to Peak Health June 26, 2024 Via InvestorPlace Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 June 26, 2024 Via InvestorPlace Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions June 24, 2024 From Corcept Therapeutics Incorporated Via GlobeNewswire While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. June 24, 2024 Via Chartmill Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
